AGA Nanotech to Attend AMR Conference in Basel as Part of Innovate UK GBIP Switzerland
At the 9th AMR Conference, AGA Nanotech will demonstrate Battlestar™, its non-antibiotic antimicrobial solution offering sustained efficacy across critical clinical applications.AGA Nanotech is excited to announce its selection for the Global Business Innovation Programme (GBIP) Switzerland: AMR, funded by Innovate UK. This five-day innovation visit will include participation in the 9th AMR Conference in Basel, offering unparalleled networking opportunities with international AMR leaders.
Through this programme, AGA Nanotech will explore collaboration opportunities in Switzerland’s major tech clusters, gain insights into market challenges, and refine its value proposition for global partners and investors.
Battlestar™ will be showcased as a breakthrough non-antibiotic antimicrobial solution offering sustained, controlled antimicrobial activity while addressing critical clinical needs in wound care, osteomyelitis, urinary tract infections, and biofilm-associated tumors.